MAPT and Alzheimer disease: GSK-3β activation or upregulation can contribute to neurodegeneration by promoting Aβ production and tau hyperphosphorylation whereas the Aβ induces neuronal damage and tau hyperphosphorylation leading to impair the formation of neurofibrillary tangles (NFTs) and their synaptic dysfunction in AD.